| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
WALTHAM, Mass.—Thermo Fisher Scientific Inc. hasacquired Proxeon A/S, a supplier of products for proteomics analysis that is headquarteredin Odense, Denmark. Thermo notes that the company "is recognized for itsability to provide a simplified proteomics workflow, including nanoflow liquidchromatography systems, columns, ion sources, and bioinformatics software, tomeet the need for robust high-sensitivity liquid chromatography/massspectrometry (LC/MS) analysis in complex proteomics applications."
 
Proxeon had revenues of approximately $10 millionin 2009 and has nearly 40 employees. Specific terms of the deal have not been disclosed, but Thermo Fisher indicates that Proxeon will be integrated into its Analytical Technologies Segment, and Thermo does not expect this transaction to have amaterial impact on its 2010 financial results.
 
 
Proxeon's nanoflow liquid chromatography system,EASY-nLC, has been adopted by a number of the world's leading proteomic centersfor what Thermo calls "its exceptional simplicity and ease of use." The system features,among other things,  an intuitivegraphical user interface, touch-screen operation and remote diagnosticscapability. The compact system footprint includes a unique autosampler, whichallows reproducible low-nanoliter injections into the mass spectrometer, reportedlypermitting researchers to improve productivity without comprising performance.The system also provides two-dimensional chromatographic capability to identifymore proteins than conventional methods, without the increased complexity ofadded valves and pumps. 
 
"By offering a high-performance solution thataddresses the need for simplified operation, we can meet the increasing demandfor LC/MS in proteomics applications," says Marc N. Casper, president and chiefexecutive officer of Thermo Fisher Scientific. "These systems can be easilyintegrated with our leading ion trap, hybrid and triple quadrupole massspectrometry systems, in line with our strategy of providing comprehensiveLC/MS solutions for both high-end research and routine applications."
  
 
 
 

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue